- Home
- AMGN vs LRCX Comparison
AMGN vs LRCX Comparison
Compare AMGN & LRCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- LRCX
- Stock Information
- Founded
- AMGN 1980
- LRCX 1980
- Country
- AMGN United States
- LRCX United States
- Employees
- AMGN N/A
- LRCX N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- LRCX Industrial Machinery/Components
- Sector
- AMGN Health Care
- LRCX Technology
- Exchange
- AMGN Nasdaq
- LRCX Nasdaq
- Market Cap
- AMGN 150.8B
- LRCX 178.4B
- IPO Year
- AMGN N/A
- LRCX N/A
- Fundamental
- Price
- AMGN $334.19
- LRCX $151.66
- Analyst Decision
- AMGN Hold
- LRCX Buy
- Analyst Count
- AMGN 14
- LRCX 26
- Target Price
- AMGN $313.31
- LRCX $144.17
- AVG Volume (30 Days)
- AMGN 3.1M
- LRCX 10.9M
- Earning Date
- AMGN 11-04-2025
- LRCX 10-22-2025
- Dividend Yield
- AMGN 2.85%
- LRCX 0.69%
- EPS Growth
- AMGN 65.12
- LRCX 46.65
- EPS
- AMGN 12.93
- LRCX 4.53
- Revenue
- AMGN $35,971,000,000.00
- LRCX $19,591,788,000.00
- Revenue This Year
- AMGN $8.82
- LRCX $17.98
- Revenue Next Year
- AMGN $1.84
- LRCX $12.21
- P/E Ratio
- AMGN $25.85
- LRCX $33.19
- Revenue Growth
- AMGN 10.56
- LRCX 25.66
- 52 Week Low
- AMGN $253.30
- LRCX $56.32
- 52 Week High
- AMGN $345.84
- LRCX $167.15
- Technical
- Relative Strength Index (RSI)
- AMGN 61.60
- LRCX 51.85
- Support Level
- AMGN $330.35
- LRCX $135.50
- Resistance Level
- AMGN $345.49
- LRCX $154.37
- Average True Range (ATR)
- AMGN 9.24
- LRCX 7.33
- MACD
- AMGN 0.26
- LRCX -2.35
- Stochastic Oscillator
- AMGN 68.68
- LRCX 50.66
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About LRCX Lam Research Corporation
Lam Research is one of the largest semiconductor wafer fabrication equipment manufacturers in the world. It specializes in deposition and etch, which entail the buildup of layers on a semiconductor and the subsequent selective removal of patterns from each layer. Lam holds the top market share in etch and holds the clear second share in deposition. It is more exposed to memory chipmakers for DRAM and NAND chips. It counts as top customers the largest chipmakers in the world, including TSMC, Samsung, Intel, and Micron.